EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Randomised Clinical Trial to Evaluate the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in X‐Linked Retinoschisis: The AXIS Trial

Jonathan Hensman iD, Hind Almushattat iD, Roselie M H Diederen, Tien-En Tan, Peilun Dai, Coen de Vente, Daniel S W Ting, Maria M van Genderen, Jeannette Ossewaarde-van Norel, Redmer van Leeuwen, Martha J H Tjon-Fo-Sang, Clara I Sánchez und 4 weitere

Clinical & Experimental Ophthalmology · 2026

DOI: 10.1111/ceo.70146 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Ophthalmology, 2026. Verfasst von Jonathan Hensman und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Amsterdam University Medical Centre, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Acetazolamide, Retinoschisis, Carbonic Anhydrase Inhibitors, Macular Edema. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Amsterdam UMC Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This trial aimed to evaluate the efficacy of oral acetazolamide in reducing cystoid fluid collections (CFC) and improving visual function in patients with X‐linked retinoschisis (XLRS).

Methods

In this investigator‐initiated, single centre, open‐label, randomised controlled trial, XLRS patients aged ≥ 12 years with fovea‐involving CFC at baseline were eligible. Participants were randomised 1:1 to receive either oral acetazolamide (500 mg/day for 16 weeks, followed by tapering or discontinuation based on response) or no treatment (control) for 32 weeks. Seven study visits were completed over 32 weeks. The primary outcome was central subfield thickness (CST). Secondary outcomes included functional and structural measures, as well as patient‐reported visual disability.

Results

A total of 19 patients were enrolled: 10 received acetazolamide (17 eyes), and nine were monitored without treatment (16 eyes). The difference in CST from baseline up to week 32 between the treatment and control groups was on average +2.7 μm ( p = 0.9; 95% CI, −68.1 to 73.5 μm). Retinal sensitivity on microperimetry showed a modest statistically significant improvement favouring acetazolamide. However, no significant improvements were observed for best‐corrected visual acuity, low‐luminance visual acuity, cystoid fluid collection volume or patient‐reported visual disability in the treatment group compared to the control group.

Conclusion

This study found no clinically meaningful benefit of oral acetazolamide for reducing CFC or improving visual function in the overall XLRS population. Although structural and functional outcomes were comparable between groups overall, a small subset of patients may experience benefit, suggesting a personalised treatment approach may be warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetazolamideRetinoschisisCarbonic Anhydrase InhibitorsMacular EdemaHumansFemaleVisual AcuityMaleAdministration, OralAdultChildTreatment OutcomeTomography, Optical CoherenceAdolescentYoung AdultMiddle AgedFollow-Up Studies

Stichwörter der Autor:innen

X‐linked juvenile retinoschisisacetazolamidecarbonic anhydrase inhibitorcentral subfield thicknesscystoid macular oedema

Substanzen

AcetazolamideCarbonic Anhydrase Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
  • Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
  • Institute of High Performance Computing, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Quantitative Healthcare Analysis (qurAI) Group, Informatics Institute, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Jonathan Hensman, Hind Almushattat

Förderung

  • Stichting Amsterdam UMC Foundation

Zitieren

APA

Hensman, J., Almushattat, H., Diederen, R. M. H., Tan, T. E., Dai, P., de Vente, C., Ting, D. S. W., van Genderen, M. M., Norel, J. O., van Leeuwen, R., Tjon-Fo-Sang, M. J. H., Sánchez, C. I., Fischer, M. D., Pfau, M., Twisk, J. W. R., & Boon, C. J. F. (2026). Randomised Clinical Trial to Evaluate the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in X‐Linked Retinoschisis: The AXIS Trial. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.70146

Vancouver

Hensman J, Almushattat H, Diederen RMH, Tan TE, Dai P, de Vente C, et al. Randomised Clinical Trial to Evaluate the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in X‐Linked Retinoschisis: The AXIS Trial. Clinical & Experimental Ophthalmology. 2026. doi:10.1111/ceo.70146

BibTeX
@article{Hensman2026,
  author = {Hensman, Jonathan and Almushattat, Hind and Diederen, Roselie M H and Tan, Tien-En and Dai, Peilun and de Vente, Coen and Ting, Daniel S W and van Genderen, Maria M and Norel, Jeannette Ossewaarde-van and van Leeuwen, Redmer and Tjon-Fo-Sang, Martha J H and Sánchez, Clara I and Fischer, M Dominik and Pfau, Maximilian and Twisk, Jos W R and Boon, Camiel J F},
  title = {Randomised Clinical Trial to Evaluate the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in X‐Linked Retinoschisis: The AXIS Trial},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2026},
  doi = {10.1111/ceo.70146}
}
Kostenlos starten →